Peptide comparison
Retatrutide vs Tirzepatide
Retatrutide and Tirzepatide are both research peptides. This side-by-side compares their mechanism, typical research dosing, half-life, routes and safety so you can see how they differ. For research use only.
Reviewed by the Helica Labs research team · Last updated August 11, 2026
| Retatrutide | Tirzepatide | |
|---|---|---|
| Category | Metabolic | Metabolic |
| Overview | Investigational once-weekly triple agonist (GIP/GLP-1/glucagon) by Eli Lilly; phase 2 data show large weight loss. Not approved. | Dual GIP/GLP-1 receptor agonist with strong human trial evidence for type 2 diabetes glycemic control and weight reduction. |
| How it works | Retatrutide is a single synthetic peptide that agonizes three incretin/metabolic receptors: GIP, GLP-1, and glucagon. GLP-1 and GIP agonism enhance glucose-dependent insulin secretion and promote satiety/slowed gastric emptying (reducing food intake), while glucagon-receptor agonism is proposed to increase energy expenditure and hepatic fat mobilization. A C20 fatty-diacid moiety promotes reversible binding to serum albumin, creating a depot effect that extends the half-life and supports once-weekly dosing. The combined appetite-suppression plus energy-expenditure mechanism is the leading hypothesis for its observed weight-loss magnitude, though the relative contribution of each receptor in humans is not fully resolved. | Tirzepatide is an acylated single-molecule peptide that simultaneously agonizes the GIP and GLP-1 receptors. GLP-1 receptor activation enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central pathways. Adding GIP agonism is thought to further augment glucose-dependent insulin response and may improve lipid handling and the tolerability/efficacy balance, producing effects on appetite and energy intake that, in trials, exceeded GLP-1 monotherapy. The net clinical result is improved glycemic control and substantial caloric-intake-driven weight loss. The relative contribution of GIP versus GLP-1 signaling in humans is still an active research question. |
| Half-life | ~6 days (supports once-weekly dosing; steady state in ~4-5 weeks) | ~5 days |
| Dosing reference | In Eli Lilly trials, retatrutide is given as a once-weekly subcutaneous injection with stepwise dose escalation to limit GI side effects. The phase 2 obesity trial used maintenance doses of 1, 4, 8, and 12 mg weekly, titrated upward over the first ~12-16 weeks (e.g., starting around 2-4 mg and increasing every 2-4 weeks). The largest weight loss occurred at 8-12 mg. These are investigational protocols; retatrutide has no approved label or established clinical dosing for general use. | Approved once-weekly subcutaneous dosing per prescribing labels: initiate at 2.5 mg once weekly for 4 weeks (a non-therapeutic initiation dose for tolerability), then increase to 5 mg; titrate in 2.5 mg increments no sooner than every 4 weeks as needed/tolerated. Approved maintenance/maximum doses are 5, 10, or 15 mg once weekly. The ~5-day half-life supports once-weekly administration with steady state reached around 4 weeks. Dosing should be individualized and supervised by a qualified clinician. |
| Routes | subcutaneous | subcutaneous |
| Safety & side effects | The most common adverse events in trials are gastrointestinal - nausea, vomiting, diarrhea, and constipation - which are dose-dependent, mostly mild-to-moderate, and concentrated during dose escalation; a lower starting dose and slower titration reduce them. Dose-dependent increases in heart rate (roughly 5-10 bpm) have been observed. Trial discontinuations due to adverse events ranged from about 6-16% across retatrutide arms. Through 48 weeks no hepatotoxicity signal was reported in the MASLD substudy, and no ketoacidosis occurred despite mild increases in ketone markers. As a glucagon-receptor agonist, blood-glucose effects warrant monitoring, particularly with concurrent diabetes medication. Long-term safety, cardiovascular outcomes, and effects of unregulated research-grade product are unknown. Class cautions for incretin agonists include pancreatitis, gallbladder issues, and a theoretical thyroid C-cell tumor signal seen in rodents. Not for use in pregnancy. Research-use-only; not approved for human consumption. | Most common adverse effects are gastrointestinal: nausea (~24-33% by dose in SURMOUNT-1), diarrhea, constipation, vomiting, and decreased appetite, generally mild-to-moderate, dose-escalation-related, and often transient; discontinuation for GI effects was relatively uncommon. Gallbladder/biliary events were slightly more frequent than placebo (e.g., ~1.1% vs ~0.4% in SURMOUNT-1), partly attributable to rapid weight loss. Meta-analysis did not show a statistically significant increase in pancreatitis versus controls, though acute pancreatitis remains a labeled caution. Rare but serious risks include severe hypersensitivity/anaphylaxis; a boxed warning addresses thyroid C-cell tumors seen in rodents (human relevance unknown) and it is contraindicated with personal/family history of medullary thyroid carcinoma or MEN 2. Hypoglycemia risk rises when combined with insulin or sulfonylureas. Not recommended in pregnancy; may reduce efficacy of oral contraceptives around dose changes due to delayed gastric emptying. Use only under medical supervision. |
For research use only. Not for human consumption. Always verify against current literature.
Frequently asked questions
- What is the difference between Retatrutide and Tirzepatide?
- Retatrutide is categorised as a Metabolic research peptide, while Tirzepatide is categorised as Metabolic. This page sets their mechanism, research dosing, half-life and routes side by side so you can compare them. Both are supplied strictly for laboratory research use only.
- What are the half-lives of Retatrutide and Tirzepatide?
- The reported half-life of Retatrutide is ~6 days (supports once-weekly dosing; steady state in ~4-5 weeks), while Tirzepatide is ~5 days. These figures are drawn from the research literature and are provided for reference only, not as dosing guidance.
- How are Retatrutide and Tirzepatide administered in research?
- In the literature, Retatrutide is studied via subcutaneous, while Tirzepatide is studied via subcutaneous. This is reference information about the compounds for laboratory research only — not directions for use.
- Can Retatrutide or Tirzepatide be used in humans?
- No. Both Retatrutide and Tirzepatide are sold strictly as research chemicals for laboratory research use only. They are not medicines, are not for human or veterinary consumption, and nothing on this page is medical or dosing advice.